AIM ImmunoTech Gets Patent Pairing Its Cancer Drug With Keytruda
Nasdaq 1 Sep · 19:00

AIM ImmunoTech Gets Patent Pairing Its Cancer Drug With Keytruda

The broadest claim covers any cancer where the two drugs work better together than apart. Ampligen has not received FDA approval to treat any form of the disease.

Read the story
Latest
How we work

Every article names the filing or release it came from. Read the source before acting on anything here.

Find them before we write about them.
Live screens — most active, gainers, losers and most volatile, US and Canada.
Open screener